Chiome: Masa Fujiwara on the Origin and Platform Technology of Chiome Biosciences




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Chiome: Masa Fujiwara on the Origin and Platform Technology of Chiome Biosciences
Released on: October 15, 2010. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks with Masa Fujiwara, CEO of Chiome, about the business model of Chiome. They discuss:
• Origin and platform technology of Chiome Biosciences

• Business model of Chiome

• ADlib technology and its advantages

• Research programs and Product pipelines

• Future plans
Origin and platform technology of Chiome Biosciences
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at the Japan Biotech Forum at the Royal Society in London. On this show I have Masa Fujiwara, who is the CEO of a company called Chiome Biosciences which is based in Japan, welcome to the show.
Masa Fujiwara:
Yes, thank you very much.
Fintan Walton:
Your company is an antibody specific company specializing in antibodies, could you tell us the origin of your company and a little bit about what your company actually does?
Masa Fujiwara:
Yes, we are based on the platform technology for antibody generation that technology we named ADLib, that abbreviation comes from Autonomously Diversifying Library. Then that technology itself was discovered by RIKEN Institution, RIKEN is a one knows that largest institution in Japan they're helping a lot from the Japanese government and then they can provide seed technology or seed products and they have a unique system named RIKEN Ventures Support System, so they like to support a startup company because as a startup company they don't have enough cash and space and people so they provide some space for their research and also they are willing to have a collaboration collaborative support with a startup company.
Business model of Chiome
Fintan Walton:
Sure, that's very important. Now the other thing of course is your company's business model, because as you said you are focused on antibodies you've got the ADLib technology that underpins that, you actually have revenues, you got cash coming in because you sell the antibodies that you generate as well could you tell us about that business model?
Masa Fujiwara:
Yes we have a three business models, one is the collaboration with these pharmaceutical company now is our main model for Chiome Biosciences and so the scheme is very simple once we conclude the contract and then the company collaborator will pay us for upfront and also they provide research fund for the duration and then if we got a nice candidate for the antibody they can give us some milestone payment and at the end if the candidate got approval some they will pay royalties, now we have a collaboration with Chugai and Novartis [PharmaDeals ID = 34945] and this is the one and the other is licensing for the antibody so by using a (indiscernable) by myself. And the third one is licensing the technology itself now who we have standardized it very much so we can start the licensing the ADLib system to the pharmaceutical companies.
ADlib technology and its advantages
Fintan Walton:
Right, so you've got three pronged approach to your business model each of them hopefully generating revenues at different points in the business cycle, so tell us a little bit about this ADLib technology, because as you say it underpins your capabilities?
Masa Fujiwara:
Yes ADLib system is a cellular antibody generation system, each cell express the antigen antibody to the surface and but our technology able to make the cell to express a different antibody, so we can create it huge diversed cell library express a different type of antibodies, so if that if you give us a cancer specific antigen we make a conjugated magnet beads as a (indiscernable) to make a fishing tool and then we fish the specific clone which recognize the antigen and so easily pick up by using magnets and once we pick up several or sometimes and more than 100 clones we make limiting dilution and to cultivate just a week the cell express a surfaced antibody and also simultaneously express to the our culture media the same specific antibody, so and we can provide the culture media containing the specific antibody, so the collaborator that can check the function or sometimes binding whatever.
Fintan Walton:
So it's really an enrichment process to identifying specific antibodies and then provides you with the appropriate clone ultimately that will generate the antibodies for research and hopefully on to products that will be of therapeutic use ultimately?
Masa Fujiwara:
Yes and the speed is very short competitive.
Fintan Walton:
So the advantage is very quick?
Masa Fujiwara:
Quick speed, yes.
Research programs and Product pipelines
Fintan Walton:
Right, so could you tell us about what products your cells are generating, what programs do you have, because you said that you've got collaborations with pharmaceutical companies and then you got your own internal research program, tell us a little bit about that?
Masa Fujiwara:
Yes, currently the our most advanced product is antibody against Semaphorin-3A the molecule is playing a main role in the nerve cell elongation, so the application would be a spinal cord injury this is the most advanced, but we have another a few pipelines based on the collaborational research with the Japanese academia along with the Cancer Research Institution in Japan [PharmaDeals ID = 36678], so it's early too early but we can generate the pipeline sequentially, so but as you've mentioned it takes a time so mean time we generate the cash from the collaboration type and then after that we like to generate the pipeline itself and to license or sometimes to collaborate with.
Fintan Walton:
Okay, now with the research programs that you've currently got underway and the products that you are looking at are those all still preclinical or they're all at the preclinical stage or have you got anything yet in clinic?
Masa Fujiwara:
Yes, still just before the preclinical stage.
Fintan Walton:
So still at discovery stage identifying the specific antibodies that could be of therapeutic value?
Masa Fujiwara:
Yes.
Future plans
Fintan Walton:
Okay, so where do you see Chiome Biosciences going forward, I mean what type of business do you see that in the next three to four years?
Masa Fujiwara:
Yes, and as you know we are very small and therefore we don't want to make huge facility so and then therefore we start licensing the technology itself amended to the large pharmaceutical company, so it's a most non risk type of deals and then mean time as I mentioned we develop the pipelines by ourselves.
Fintan Walton:
Masa Fujiwara, thank you very much for coming on the show.
Masa Fujiwara:
Thank you very much.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Masa Fujiwara
Chief Executive Officer
Masa Fujiwara D.V.M has wide experiences in science and business in pharmaceutical industry in Japan. Masa Fujiwara also has consulting and management skills through his career. From February 2005, Masa Fujiwara has been the President & CEO of the Chiome Biosciences Inc. He worked at Chugai Pharmaceutical Co Ltd and IBM Business Consulting Service. He served as Director, Data Management Dept. in Quintiles Transnational Japan K.K and then became Chief Executive Officer in February 2005.Masa Fujiwara graduated University of Tokyo, Agriculture Faculty, Master Course in D.V.M.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Chiome Biosciences
The Chiome Biosciences Inc.,(CBI)was established on February 8th, 2005 for the purpose of introducing and commercializing the state-of-the-art ADLibtherapeutic antibody generation technology. CBI has been officially certified as a RIKEN Venture Company. The "ADLib" system was developed in RIKEN's Gene Dynamics Unit, headed by Dr. Kunihiro Ohta, taking advantage of his extensive knowledge and experience with homologous recombination. ADLib is a next-generation technology that can develop monoclonal antibodies in vitro in only two weeks. This technology also makes it possible to develop high-affinity antibodies against refractory antigens that cannot be addressed by legacy hybridoma technology. Moreover, because it is a non-immune based system, ADLib can provide a theoretically limitless variety of B cells, each expressing a different antibody. Thus it becomes possible to develop high-avidity antibodies against typically tough antigens such as pathogens, and to discriminate against protein targets or epitopes that are highly homologous or conserved among species. Chiome Biosciences Inc. is striving to become an international biotech company through global eXchange, as signified by the company's name and logo depicting the X-shaped conjunction of two chromosomes.